ValuEngine Downgrades Cerus (CERS) to Buy

ValuEngine lowered shares of Cerus (NASDAQ:CERS) from a strong-buy rating to a buy rating in a report issued on Monday morning.

Several other equities analysts also recently weighed in on the company. BidaskClub downgraded Cerus from a sell rating to a strong sell rating in a research report on Wednesday, November 7th. Zacks Investment Research downgraded Cerus from a buy rating to a hold rating in a research report on Friday, October 5th. Cantor Fitzgerald reiterated a buy rating and set a $9.00 target price on shares of Cerus in a research report on Wednesday, October 3rd. Finally, Cowen set a $10.00 target price on Cerus and gave the company a buy rating in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Cerus currently has an average rating of Hold and an average target price of $8.00.

NASDAQ CERS traded up $0.06 on Monday, hitting $5.11. 52,425 shares of the company traded hands, compared to its average volume of 1,105,545. The company has a market capitalization of $715.08 million, a PE ratio of -8.96 and a beta of 1.54. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.17 and a current ratio of 3.48. Cerus has a 52-week low of $3.35 and a 52-week high of $8.05.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, November 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.11). The company had revenue of $15.40 million for the quarter, compared to the consensus estimate of $15.40 million. Cerus had a negative return on equity of 68.90% and a negative net margin of 74.95%. Cerus’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.12) earnings per share. On average, sell-side analysts forecast that Cerus will post -0.43 EPS for the current year.

In related news, CFO Kevin Dennis Green sold 50,000 shares of Cerus stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $7.50, for a total value of $375,000.00. Following the completion of the transaction, the chief financial officer now owns 110,825 shares in the company, valued at $831,187.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 58,349 shares of company stock worth $427,571 over the last ninety days. Insiders own 6.80% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in shares of Cerus in the 1st quarter worth about $107,000. First Quadrant L P CA acquired a new stake in shares of Cerus in the 3rd quarter worth about $112,000. Advisory Services Network LLC acquired a new stake in shares of Cerus in the 2nd quarter worth about $130,000. Paloma Partners Management Co acquired a new stake in shares of Cerus in the 2nd quarter worth about $150,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of Cerus in the 2nd quarter worth about $183,000. 58.69% of the stock is owned by hedge funds and other institutional investors.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

See Also: Earnings Per Share (EPS)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply